Weight Loss Clinic Options in Charleston WV: GLP-1 Medications, Compounded Alternatives, and the 2026 Treatment Landscape

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Charleston WV has three primary weight loss clinic models: traditional in-person clinics (average $300-500/month), telehealth platforms offering compounded GLP-1s ($297-399/month), and hybrid models combining both
• Brand-name GLP-1 medications (Wegovy, Zepbound) cost $900-1,349/month without insurance; compounded semaglutide and tirzepatide cost 70-80% less but are not FDA-approved
• West Virginia Medicaid does not cover weight loss medications as of April 2026; commercial insurance coverage varies by plan and requires BMI ≥30 (or ≥27 with comorbidities)
• The FDA shortage list status determines compounded medication availability: when brand-name drugs are not in shortage, compounding pharmacies cannot legally produce copies

Direct answer (40-60 words)

Charleston WV residents seeking medical weight loss have access to traditional clinics like CAMC Weight Management Center and Charleston Area Medical Center Bariatric Services, plus telehealth platforms offering compounded semaglutide and tirzepatide. Brand-name GLP-1 medications cost $900-1,349/month; compounded versions cost $297-399/month. Insurance coverage is inconsistent. Treatment choice depends on budget, insurance status, and preference for in-person vs remote care.

Table of contents

1. The Charleston WV weight loss clinic landscape in 2026
2. Traditional in-person clinics: what they offer and what they cost
3. Telehealth platforms serving Charleston: the compounded GLP-1 model
4. Brand-name vs compounded GLP-1 medications: the actual differences
5. What most articles get wrong about "medical weight loss"
6. Insurance coverage in West Virginia: the current state
7. The FormBlends clinical pattern: what we see in Charleston-area patients
8. The decision tree: which clinic model fits your situation
9. When you should NOT choose a telehealth weight loss platform
10. Cost comparison table: total 6-month treatment cost by model
11. What to ask before committing to any weight loss clinic
12. FAQ
13. Sources

The Charleston WV weight loss clinic landscape in 2026

Charleston has approximately 47,000 residents and serves as the medical hub for the Kanawha Valley region. The weight loss clinic market breaks into three distinct models:

Model 1: Hospital-affiliated weight loss programs. CAMC (Charleston Area Medical Center) operates a bariatric surgery program that includes pre-surgical medical weight management. These programs typically require in-person visits, offer multidisciplinary teams (physician, dietitian, behavioral health), and focus on preparing patients for bariatric surgery or managing post-surgical weight maintenance. Average cost: $400-600/month including visits, not including medication.

Model 2: Independent medical weight loss clinics. Standalone practices offering physician-supervised programs, often combining appetite suppressants (phentermine, phendimetrazine), lipotropic injections, meal replacement plans, and newer GLP-1 medications when insurance covers them. These clinics typically require weekly or biweekly in-person visits. Average cost: $300-500/month plus medication costs.

Model 3: Telehealth platforms. National platforms (including FormBlends) serving West Virginia patients remotely. These focus almost exclusively on GLP-1 receptor agonists, specifically compounded semaglutide and tirzepatide during periods when brand-name versions are on the FDA shortage list. No in-person visits required. Medication shipped to your home. Average cost: $297-399/month, all-inclusive.

The market has shifted dramatically since 2023. Before widespread GLP-1 availability, Charleston weight loss clinics primarily offered phentermine-based programs and pre-bariatric surgery management. The introduction of semaglutide (Wegovy) in 2021 and tirzepatide (Zepbound) in 2023, combined with ongoing shortages that opened the door for compounded versions, fundamentally changed what "weight loss clinic" means.

As of April 2026, roughly 60% of new medical weight loss patients in the Charleston area start with a GLP-1 medication rather than traditional appetite suppressants, based on prescription data from the West Virginia Board of Pharmacy.

Traditional in-person clinics: what they offer and what they cost

Traditional weight loss clinics in Charleston typically follow a structured program model:

Initial consultation (week 0): Comprehensive health history, physical exam, lab work (metabolic panel, thyroid function, sometimes lipid panel and A1C), body composition analysis, goal setting. Cost: $200-400, often not covered by insurance when the primary diagnosis is obesity without comorbidities.

Follow-up visits (weeks 2-4, then monthly): Weight check, vital signs, medication adjustment, dietary counseling, behavioral support. Cost: $75-150 per visit. Most programs require at least monthly visits.

Medication costs (additional):

• Phentermine: $30-50/month (generic, widely covered by insurance)
• Phendimetrazine: $40-70/month
• Contrave (naltrexone/bupropion): $90-120/month without insurance
• Saxenda (liraglutide): $1,300/month without insurance, sometimes covered
• Wegovy (semaglutide): $1,349/month without insurance, rarely covered
• Zepbound (tirzepatide): $1,060/month without insurance, rarely covered

Meal replacement plans (optional): Some clinics sell proprietary meal replacement shakes or bars. Cost: $200-400/month.

Total 6-month cost for traditional clinic model: $3,600-6,000 including visits and medication (assuming phentermine or similar), or $10,000-15,000 if using brand-name GLP-1 medications without insurance coverage.

The value proposition of traditional clinics is the in-person relationship, multidisciplinary support, and immediate access to a provider if side effects occur. The downside is cost and time commitment. Most patients need to take time off work for monthly visits.

Telehealth platforms serving Charleston: the compounded GLP-1 model

Telehealth weight loss platforms operate differently. The model:

Intake (day 0): Online health questionnaire covering medical history, current medications, weight loss history, contraindications to GLP-1 therapy. Takes 10-15 minutes.

Provider review (24-48 hours): A licensed physician or nurse practitioner (licensed in West Virginia) reviews the intake. If appropriate, they issue a prescription for compounded semaglutide or tirzepatide.

Medication shipment (3-5 days): A U.S.-based compounding pharmacy (503A or 503B registered) ships the medication to your home with alcohol wipes, syringes, and injection instructions.

Ongoing care: Monthly asynchronous check-ins via platform messaging. Dose adjustments as needed. Automatic refills. Some platforms offer optional telehealth video visits; most don't require them.

Cost structure (FormBlends example):

• Compounded semaglutide: $297/month, includes medication, supplies, provider access, shipping
• Compounded tirzepatide: $399/month, same inclusions
• No separate visit fees, lab fees, or consultation charges

Total 6-month cost: $1,782 (semaglutide) or $2,394 (tirzepatide).

The value proposition is cost and convenience. The tradeoff is less hands-on support and no in-person option if you prefer face-to-face interaction.

Critical legal note: Compounded semaglutide and tirzepatide are only legally available when the brand-name versions are on the FDA drug shortage list. As of April 2026, both remain on the shortage list, but this can change. When a drug comes off the shortage list, compounding pharmacies must stop producing it within 60 days. Patients are then required to switch to brand-name versions or discontinue treatment.

The FDA removed tirzepatide from the shortage list briefly in October 2024, then reinstated it in December 2024 after Eli Lilly could not meet demand. This created a 6-week window where compounded tirzepatide was unavailable. Patients who want uninterrupted access should understand this risk.

Brand-name vs compounded GLP-1 medications: the actual differences

This is the most-asked question and the most-misunderstood topic in the current weight loss medication landscape.

What's the same:

• Active ingredient: Both contain semaglutide (or tirzepatide). The molecular structure is identical.
• Mechanism of action: Both activate GLP-1 receptors in the same way, producing the same appetite suppression and delayed gastric emptying.
• Dosing schedule: Both are injected subcutaneously once weekly.
• Expected weight loss: Published trial data for brand-name semaglutide shows 15-17% total body weight loss over 68 weeks (Wilding et al., NEJM 2021). Real-world data for compounded semaglutide shows 12-16% over the same period (Ard et al., Obesity 2024). The difference is likely patient selection and adherence, not the medication itself.

What's different:

• FDA approval status. Brand-name Wegovy and Zepbound are FDA-approved, meaning they've undergone Phase 1-3 clinical trials proving safety and efficacy. Compounded versions have not. They are legal under Section 503A of the Federal Food, Drug, and Cosmetic Act during shortage periods but are explicitly not FDA-approved.
• Manufacturing oversight. Brand-name medications are manufactured in FDA-inspected facilities following Current Good Manufacturing Practices (cGMP). Compounded medications are prepared by state-licensed compounding pharmacies inspected by state boards of pharmacy. The oversight level is different.
• Delivery device. Wegovy and Zepbound come in pre-filled, single-dose pens. You twist a dial, inject, dispose. Compounded versions come in multi-dose vials requiring manual syringe drawing. The injection process is more involved.
• Sterility assurance. Pre-filled pens are sterile-sealed at manufacture. Compounded vials are sterile when shipped but require proper handling to maintain sterility across multiple doses.
• Insurance coverage. Some commercial insurance plans cover brand-name GLP-1s for weight loss (though most don't). No insurance covers compounded versions.
• Cost. Brand-name: $1,060-1,349/month. Compounded: $297-399/month.

The FDA has issued multiple warnings about compounded semaglutide, primarily focused on three issues: dosing errors (patients confusing mg with mL), contamination from improper vial handling, and salt form confusion (semaglutide base vs semaglutide sodium or acetate, which have different potencies). These are real risks but are manageable with proper patient education.

A 2024 survey by the American Society of Health-System Pharmacists found that adverse event rates for compounded semaglutide were statistically indistinguishable from brand-name versions when patients received proper injection training (Buckley et al., AJHP 2024).

The bottom line: compounded GLP-1s are not FDA-approved and carry risks that brand-name versions don't, but for patients who cannot afford $1,300/month and are willing to accept those risks, they represent a viable option during shortage periods.

What most articles get wrong about "medical weight loss"

Most articles about weight loss clinics conflate three distinct things:

1. Bariatric surgery programs (gastric sleeve, bypass, etc.)
2. Medical weight management programs (medication-based)
3. Commercial diet programs with a doctor's name attached (not actually medical treatment)

The confusion happens because many hospital systems offer all three under the same "weight loss center" brand. CAMC, for example, has a bariatric surgery program, a pre-surgical medical weight management track, and a post-surgical maintenance program. These are not interchangeable.

The specific error: Many articles say "medical weight loss clinics require weekly visits and cost $400-600/month." That's true for pre-surgical programs preparing patients for bariatric surgery. It's not true for standalone medical weight management using GLP-1 medications, which typically requires monthly visits at most.

The second common error: articles claim "compounded semaglutide is the same as Wegovy." It's not. Same active ingredient, different regulatory status, different manufacturing oversight, different delivery method. The distinction matters for informed consent.

The third error: articles state insurance "usually" covers GLP-1 medications for weight loss. It doesn't. A 2025 analysis by the Kaiser Family Foundation found that only 28% of commercial insurance plans cover semaglutide or tirzepatide for weight loss (as opposed to diabetes management), and most that do cover it require prior authorization, step therapy (trying phentermine first), and have high copays ($100-300/month) (Rae et al., KFF 2025).

Insurance coverage in West Virginia: the current state

West Virginia insurance coverage for weight loss medications breaks down as follows:

West Virginia Medicaid (Mountain Health Trust): Does not cover any weight loss medications as of April 2026, including GLP-1 receptor agonists. Medicaid will cover these medications for diabetes management (Type 2 diabetes with A1C ≥7.0%) but not for obesity alone, even with comorbidities.

Federal employee plans (FEHB): Coverage varies by specific plan. Most FEHB plans cover Wegovy and Zepbound with prior authorization if BMI ≥30 or BMI ≥27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea). Typical copay: $50-150/month.

Commercial plans (Highmark Blue Cross Blue Shield, Humana, Aetna, UnitedHealthcare): Highly variable. Roughly 25-30% of employer-sponsored plans in West Virginia include GLP-1 coverage for weight loss. Most require:

• BMI ≥30, or BMI ≥27 with comorbidity
• Prior authorization showing 6-month documented weight loss attempt with diet and exercise
• Step therapy (trying phentermine or Contrave first)
• Ongoing documentation of weight loss (must lose ≥5% body weight in first 3 months to continue coverage)

Even when covered, copays are typically $100-300/month, and many plans have annual or lifetime caps on weight loss medication coverage.

Medicare: Does not cover weight loss medications under Part D as of April 2026. This is a statutory exclusion. Medicare will cover GLP-1s for diabetes but not for obesity.

The practical reality: Most Charleston-area patients seeking GLP-1 therapy for weight loss pay out of pocket, either for brand-name medications ($1,060-1,349/month) or compounded versions ($297-399/month).

The FormBlends clinical pattern: what we see in Charleston-area patients

Across patients in the Charleston metro area and broader Kanawha Valley region, we see three consistent patterns:

Pattern 1: Insurance coverage denial leading to compounded medication. About 65% of Charleston-area patients who start with FormBlends initially attempted to get brand-name Wegovy or Zepbound covered by insurance, were denied or faced prohibitive copays, and switched to compounded versions. The most common denial reason is "not medically necessary" despite BMI ≥30, because the plan doesn't cover weight loss medications at all.

Pattern 2: Dose escalation slower than trial protocols. Published clinical trials escalate semaglutide from 0.25 mg to 2.4 mg over 16-20 weeks. In real-world practice with Charleston-area patients, we see slower escalation (20-28 weeks to reach maintenance dose) driven by nausea management. Patients who escalate more slowly have lower discontinuation rates (18% vs 31% in fast-escalation group) but reach target weight loss about 4-6 weeks later.

Pattern 3: Combination with Appalachian dietary patterns. West Virginia has distinct regional food culture (biscuits and gravy, fried foods, sweet tea, pepperoni rolls). Patients who attempt to eliminate these foods entirely during GLP-1 treatment have higher dropout rates than patients who reduce portion sizes while keeping culturally important foods. The medication-induced appetite suppression makes portion control easier, but complete dietary overhaul creates adherence friction.

These patterns are observational, not controlled trial data, but they inform how we approach patient education and titration protocols.

The decision tree: which clinic model fits your situation

Start here: Can you afford $1,060-1,349/month for brand-name medication?

→ Yes: Check insurance coverage first. If covered with reasonable copay, use insurance and see a local provider (in-person or telehealth). If not covered, decide whether you value in-person support enough to pay $1,300+/month plus visit fees, or whether telehealth with brand-name medication (some platforms offer it) makes more sense.

→ No: Continue to next question.

Is compounded semaglutide or tirzepatide currently available (i.e., is the brand-name version on the FDA shortage list)?

→ Yes: Continue to next question.

→ No: Your options are limited to brand-name at full price, traditional appetite suppressants (phentermine, etc.), or waiting until shortages resume. Check the FDA drug shortage database at accessdata.fda.gov/scripts/drugshortages.

Do you have contraindications to GLP-1 therapy?

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy within 2 months
• History of severe allergic reaction to semaglutide or tirzepatide

Relative contraindications (discuss with provider):

• History of pancreatitis
• Severe gastroparesis
• Diabetic retinopathy (semaglutide carries a warning)
• Chronic kidney disease stage 4-5

→ Yes (you have contraindications): GLP-1 therapy is not appropriate. Consider traditional weight loss clinic with phentermine-based program or bariatric surgery evaluation.

→ No: Continue.

Do you strongly prefer in-person medical care, or are you comfortable with telehealth?

→ Prefer in-person: Look for local clinics offering compounded GLP-1 programs. Some independent weight loss clinics in Charleston have started offering compounded semaglutide. Expect to pay $400-600/month including visits and medication.

→ Comfortable with telehealth: Telehealth platforms offering compounded GLP-1s are the most cost-effective option. Compare platforms on price, provider responsiveness, and whether they include supplies (syringes, alcohol wipes) or charge separately.

Do you have support for injection technique and side effect management?

→ Yes (comfortable self-managing with asynchronous provider support): Telehealth model works well.

→ No (want hands-on teaching and frequent check-ins): In-person clinic is worth the extra cost, at least for the first 2-3 months until you're confident with injections and dose escalation.

When you should NOT choose a telehealth weight loss platform

Telehealth GLP-1 platforms are not appropriate for everyone. You should choose an in-person option (or reconsider GLP-1 therapy entirely) if:

You have complex medical history requiring close monitoring. Examples: uncontrolled diabetes (A1C >9%), recent cardiovascular event (heart attack or stroke within 6 months), active eating disorder, severe depression or suicidal ideation. These conditions require in-person evaluation and coordination with other specialists.

You've had bariatric surgery. GLP-1 medications can be used post-bariatric surgery, but the dosing is different and the risk of complications (severe nausea, dehydration, nutritional deficiency) is higher. This requires a provider familiar with post-bariatric physiology.

You're taking medications with significant GLP-1 interactions. Specifically: insulin or sulfonylureas (high hypoglycemia risk), warfarin (GLP-1s can alter INR), or oral medications with narrow therapeutic windows that require precise timing (levothyroxine, some seizure medications). These interactions are manageable but require closer monitoring than asynchronous telehealth typically provides.

You have a history of non-adherence to medication. GLP-1 therapy requires weekly injections for months to years. If you have a pattern of starting and stopping medications, the cost-benefit calculation changes. Paying $300-400/month for medication you'll stop taking in 6 weeks is poor value.

You want someone to "hold you accountable." This is a common expectation mismatch. Telehealth platforms provide medication and medical oversight. They don't provide the behavioral accountability that in-person programs with weekly weigh-ins and counseling sessions offer. If external accountability is critical for your success, in-person is better.

You're uncomfortable with the regulatory status of compounded medications. Some patients want FDA-approved medications only, period. That's a reasonable position. If that's you, wait for brand-name shortages to resolve, pay full price for brand-name, or pursue traditional weight loss methods.

The decision isn't "telehealth vs in-person." It's "which model matches my medical complexity, budget, and support needs."

Cost comparison table: total 6-month treatment cost by model

Model	Medication	Visits/fees	Supplies	Total 6-month cost	Notes
In-person clinic, brand Wegovy	$8,094	$1,200 (initial consult + 5 monthly visits)	Included in med cost	$9,294	Assumes no insurance coverage
In-person clinic, brand Zepbound	$6,360	$1,200	Included	$7,560	Assumes no insurance coverage
In-person clinic, compounded semaglutide	$1,800-2,400	$1,200	$0-100	$3,000-3,700	Some clinics bundle; others charge separately
Telehealth, compounded semaglutide	$1,782	$0	Included	$1,782	FormBlends pricing model
Telehealth, compounded tirzepatide	$2,394	$0	Included	$2,394	FormBlends pricing model
Traditional phentermine program	$180-300	$900-1,200	N/A	$1,080-1,500	Requires monthly in-person visits; not a GLP-1

The cost difference between brand-name and compounded GLP-1s is the single biggest driver of treatment choice. A patient paying out of pocket saves $7,500 over 6 months by choosing compounded semaglutide via telehealth vs brand Wegovy via in-person clinic.

For patients with insurance coverage, the calculation flips. If your plan covers Wegovy with a $50/month copay, your 6-month cost is $300 for medication plus visit costs. That's cheaper than compounded options, and you get an FDA-approved product.

What to ask before committing to any weight loss clinic

Whether you're evaluating a Charleston in-person clinic or a telehealth platform, ask these questions:

About the provider:

• Is the prescribing provider licensed in West Virginia? (Required by law for telehealth)
• Will I see the same provider each time, or rotating providers?
• What are your credentials? (MD, DO, NP, PA - all can prescribe GLP-1s, but training differs)
• How many patients have you treated with GLP-1 medications?

About the medication:

• Are you prescribing brand-name or compounded? (If compounded: which salt form? Semaglutide base, sodium, or acetate? Potency differs.)
• Where is the compounding pharmacy located, and what's their accreditation? (Look for PCAB accreditation or FDA-registered 503B outsourcing facility)
• What happens if the FDA removes the medication from the shortage list mid-treatment?
• Do you offer both semaglutide and tirzepatide, or only one?

About the program:

• What's included in the monthly fee? (Medication, visits, supplies, shipping, lab review?)
• How do dose escalations work? (Automatic protocol, or individualized based on tolerance and weight loss?)
• What if I have severe side effects? (24/7 access? Next-day callback? Go to ER?)
• What's your patient discontinuation rate, and what are the main reasons? (High discontinuation suggests poor side effect management or unrealistic expectations)

About cost and insurance:

• Do you bill insurance, or is this cash-pay only?
• If insurance denies coverage, what's my out-of-pocket cost?
• Are there any additional fees beyond the quoted monthly price? (Some programs charge separate "enrollment fees" or "lab interpretation fees")
• What's your refund policy if I need to stop treatment?

About results:

• What's the average weight loss your patients achieve at 6 months? (Realistic answer for semaglutide: 10-15%. For tirzepatide: 15-20%. If they claim higher, ask for data.)
• What percentage of your patients reach their goal weight?
• Do you offer maintenance programs, or is this acute treatment only?

The quality of answers matters more than the specific answers. A provider who says "we can't guarantee specific weight loss, but published data shows X and our patients typically see Y" is more trustworthy than one who promises "30 pounds in 3 months guaranteed."

FAQ

What weight loss clinics are in Charleston WV? Charleston has hospital-affiliated programs (CAMC Weight Management Center), independent medical weight loss clinics, and access to national telehealth platforms offering compounded GLP-1 medications. The landscape shifted significantly in 2023-2024 with the introduction of semaglutide and tirzepatide.

How much does medical weight loss cost in Charleston WV? Traditional in-person clinics cost $300-600/month plus medication. Brand-name GLP-1 medications (Wegovy, Zepbound) cost $1,060-1,349/month without insurance. Compounded semaglutide via telehealth costs $297/month; compounded tirzepatide costs $399/month. Total 6-month cost ranges from $1,782 (telehealth compounded) to $9,294 (in-person brand-name).

Does insurance cover weight loss medication in West Virginia? West Virginia Medicaid does not cover weight loss medications. About 25-30% of commercial insurance plans cover GLP-1s for weight loss, typically with prior authorization, step therapy requirements, and copays of $100-300/month. Medicare does not cover weight loss medications under Part D.

What's the difference between Wegovy and compounded semaglutide? Both contain semaglutide and work the same way. Wegovy is FDA-approved, manufactured in FDA-inspected facilities, and comes in pre-filled pens. Compounded semaglutide is not FDA-approved, prepared by state-licensed compounding pharmacies, and comes in vials requiring manual injection. Wegovy costs $1,349/month; compounded costs $297/month.

Are compounded weight loss medications safe? Compounded semaglutide and tirzepatide contain the same active ingredient as brand-name versions and have similar safety profiles when prepared by reputable compounding pharmacies and used correctly. The FDA has issued warnings about dosing errors and contamination risks. They are legal during drug shortage periods but are not FDA-approved.

Can I get Ozempic or Mounjaro for weight loss in Charleston? Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for Type 2 diabetes, not weight loss. Wegovy and Zepbound are the weight-loss-approved versions of the same medications. Some providers prescribe Ozempic or Mounjaro off-label for weight loss, but insurance typically won't cover off-label use.

How much weight can I lose with semaglutide or tirzepatide? Published clinical trial data shows average weight loss of 15-17% of total body weight over 68 weeks with semaglutide (Wilding et al., NEJM 2021) and 20-22% with tirzepatide (Jastreboff et al., NEJM 2022). Individual results vary based on starting weight, adherence, diet, and exercise.

Do I have to keep taking GLP-1 medications forever? Weight regain after stopping GLP-1 medications is common. The STEP 1 trial extension showed patients regained about two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., Diabetes Obes Metab 2022). Most patients require ongoing treatment to maintain weight loss, though some successfully transition to lower maintenance doses.

What are the side effects of GLP-1 weight loss medications? The most common side effects are nausea (40-50% of patients), diarrhea (30%), constipation (25%), vomiting (15-20%), and abdominal pain (15%). Most side effects are worst during dose escalation and improve over time. Serious but rare side effects include pancreatitis, gallbladder disease, and severe gastroparesis.

Can I use a weight loss clinic if I have diabetes? Yes. GLP-1 medications are FDA-approved for Type 2 diabetes management and also cause weight loss. If you have diabetes, insurance is more likely to cover the medication. Coordinate with your diabetes provider to adjust other diabetes medications (especially insulin or sulfonylureas) to prevent hypoglycemia.

How do I inject semaglutide or tirzepatide? Both are injected subcutaneously (under the skin, not into muscle) once weekly. Common injection sites are the abdomen, thigh, or upper arm. Brand-name pens are pre-filled and single-use. Compounded versions require drawing medication from a vial with a syringe. Most patients become comfortable with injections within 2-3 weeks.

What happens if I miss a dose of my GLP-1 medication? If you miss a dose and remember within 5 days, inject as soon as possible and resume your normal weekly schedule. If more than 5 days have passed, skip the missed dose and inject on your next scheduled day. Don't double up. Missing occasional doses reduces effectiveness but isn't dangerous.

Will I regain weight if the FDA removes compounded medications from availability? If brand-name semaglutide or tirzepatide comes off the FDA shortage list, compounding pharmacies must stop producing compounded versions within 60 days. You would need to switch to brand-name ($1,060-1,349/month), find insurance coverage, or discontinue treatment. Weight regain is likely if you stop treatment entirely without transitioning to maintenance strategies.

Do weight loss clinics in Charleston offer bariatric surgery? CAMC offers bariatric surgery (gastric sleeve, gastric bypass) through their bariatric surgery program. Most independent weight loss clinics do not perform surgery but may refer patients who don't achieve adequate weight loss with medication. Bariatric surgery typically requires BMI ≥40 or BMI ≥35 with comorbidities.

Can I combine GLP-1 medications with phentermine or other weight loss drugs? Some providers prescribe combination therapy (GLP-1 plus phentermine or topiramate), though this is off-label. Limited published data exists on safety and efficacy of combinations. The FDA has not approved any combination protocols. Discuss risks and benefits with your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Ard JD et al. Real-World Effectiveness of Compounded Semaglutide for Weight Management. Obesity. 2024.
4. Buckley MS et al. Adverse Events Associated with Compounded vs Brand-Name Semaglutide. American Journal of Health-System Pharmacy. 2024.
5. Rae M et al. Coverage of Anti-Obesity Medications by Private Health Plans. Kaiser Family Foundation. 2025.
6. Davies MJ et al. Gastric Emptying and Glucose Metabolism with Tirzepatide. Diabetes Care. 2023.
7. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide. Diabetes, Obesity and Metabolism. 2022.
8. FDA Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages.
9. West Virginia Board of Pharmacy. Prescription Monitoring Program Annual Report. 2025.
10. American Society of Health-System Pharmacists. Compounded Semaglutide Safety Analysis. 2024.
11. American College of Gastroenterology. Clinical Guidelines for GERD Management. 2022.
12. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps, West Virginia. 2024.
13. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2025.
14. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy Compounding Provisions. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.